{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:25:12Z","timestamp":1790313912093,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012502","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000}}],"reference-count":246,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012502.pub2","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T13:42:19Z","timestamp":1543326139000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events"],"prefix":"10.1002","volume":"2018","author":[{"given":"Shipeng","family":"Zhan","sequence":"first","affiliation":[{"name":"First Affiliated Hospital of Third Military Medical University (Army Medical University); Pharmacy Department; 30 Gaotanyan Street Shapingba District Chongqing China 400038"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tang","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Third Military Medical University (Army Medical University); Pharmacy Department; 30 Gaotanyan Street Shapingba District Chongqing China 400038"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Third Military Medical University (Army Medical University); Pharmacy Department; 30 Gaotanyan Street Shapingba District Chongqing China 400038"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyuan","family":"Xia","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Third Military Medical University (Army Medical University); Pharmacy Department; 30 Gaotanyan Street Shapingba District Chongqing China 400038"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoqin","family":"Shu","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Third Military Medical University (Army Medical University); Cardiovascular Department; Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiao","family":"Wu","sequence":"additional","affiliation":[{"name":"Third Military Medical University (Army Medical University); Department of Health Statistics, College of Preventive Medicine; Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,11,19]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD012502.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1368-5031.2004.00278.x","article-title":"Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia","volume":"58","author":"Ballantyne","year":"2004","journal-title":"International Journal of Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD012502.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5551\/jat.35626","article-title":"Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study","volume":"24","author":"Oikawa","year":"2017","journal-title":"Journal of Atherosclerosis & Thrombosis"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"E230","DOI":"10.1016\/j.atherosclerosis.2016.07.217","article-title":"Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study","volume":"252","author":"Oikawa","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0004|cit4","unstructured":"UMIN000001224 Effect of fenofibrate and ezetimibe combination treatment on lipid http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000001224"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1567-5688(03)91468-1","article-title":"The ENHANCE trial: Ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression","volume":"4","author":"Kastelein","year":"2003","journal-title":"Atherosclerosis Supplements"},{"issue":"14","key":"10.1002\/14651858.CD012502.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD012502.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1056\/NEJMx080011","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia.[Erratum]","volume":"358","author":"Kastelein","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ahj.2004.06.024","article-title":"Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial","volume":"149","author":"Kastelein","year":"2005","journal-title":"American Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD012502.pub2-BIB0009|cit9","first-page":"E258","article-title":"The ENHANCE Trial: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression","volume":"35","author":"Kastelein","year":"2004","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0010|cit10","unstructured":"NCT00552097 Effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (ENHANCE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00552097"},{"issue":"SUPPL 3","key":"10.1002\/14651858.CD012502.pub2-BIB0011|cit11","first-page":"14134","article-title":"Effects of statin plus ezetimibe versus statin alone on coronary atherosclerosis in acute coronary syndrome","volume":"132","author":"Hibi","year":"2015","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD012502.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1253\/circj.CJ-17-0598","article-title":"Effects of ezetimibe-statin combination therapy on coronary atherosclerosis in acute coronary syndrome","volume":"82","author":"Hibi","year":"2018","journal-title":"Circulation Journal"},{"issue":"29","key":"10.1002\/14651858.CD012502.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","article-title":"Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial","volume":"38","author":"Hagiwara","year":"2017","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Kanbayashi K Yamaguchi J Fujii S Kawada-Watanabe E Arashi H Sekiguchi H The impact of serum sitosterol level on clinical outcomes in acute coronary syndrome patients with dyslipidemia: a subanalysis of HIJ PROPER European Heart Journal 2017 237","DOI":"10.1093\/eurheartj\/ehx502.P1119"},{"issue":"3","key":"10.1002\/14651858.CD012502.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jjcc.2016.05.002","article-title":"Rationale, design features, and baseline characteristics: the Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER)","volume":"69","author":"Kawada-Watanabe","year":"2017","journal-title":"Journal of Cardiology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012502.pub2-BIB0016|cit16","first-page":"A18891","article-title":"Impact of type 2 diabetes on optimal target LDLC level for secondary prevention of cardiovascular disease in patients with acute coronary syndrome: A subanalysis of HIJPROPER","volume":"136","author":"Sekiguchi","year":"2017","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0017|cit17","unstructured":"UMIN000002742 Proper Level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000002742"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012502.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"A53","DOI":"10.1016\/S0735-1097(18)30594-1","article-title":"Impact of high sensitivity C reactive protein levelon clinical outcomes of acute coronary syndrome patients with dyslipidemia undergoing contemporary lipid lowering therapy","volume":"71","author":"Watanabe","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.atherosclerosis.2018.04.036","article-title":"Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HIJ-PROPER","volume":"274","author":"Yamaguchi","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0020|cit20","unstructured":"Ambrosy AP Cerbin LP Clare R Lokhnygina Y Tershakovec A Roe Mt The natural history of patients post-acute coronary syndrome based on heart failure status-an analysis of the improve-it trial Circulation 2017 A17275"},{"issue":"SUPPL 3","key":"10.1002\/14651858.CD012502.pub2-BIB0021|cit21","first-page":"A16708","article-title":"Increasing age and the benefit from higher-intensity lipid lowering with ezetimibe\/simvastatin vs. simvastatin alone: Results from the IMPROVE-IT trial","volume":"132","author":"Bach","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ahj.2014.05.004","article-title":"Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population","volume":"168","author":"Blazing","year":"2014","journal-title":"American Heart Journal"},{"issue":"23","key":"10.1002\/14651858.CD012502.pub2-BIB0023|cit23","first-page":"2112","article-title":"On-Treatment Analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)","volume":"130","author":"Blazing","year":"2014","journal-title":"Circulation"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0024|cit24","first-page":"1151","article-title":"Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects randomized to simvastatin or ezetimibe\/simvastatin in the IMPROVE-IT study","volume":"36","author":"Blazing","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ahj.2016.09.004","article-title":"On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)","volume":"182","author":"Blazing","year":"2016","journal-title":"American Heart Journal"},{"issue":"13","key":"10.1002\/14651858.CD012502.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD012502.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Bohula EA Wiviott SD Giugliano RP Blazing MA Park JG Murphy SA Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Circulation 2017 2440 50","DOI":"10.1161\/CIRCULATIONAHA.117.029095"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0029|cit29","first-page":"1060","article-title":"Achievement of dual LDL-C (<70 mg\/dL) and hs-CRP (<2 mg\/L) goals more frequent with addition of ezetimibe and associated with better outcomes in IMPROVE-IT","volume":"36","author":"Bohula May","year":"2015","journal-title":"European Heart Journal"},{"issue":"10 SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0030|cit30","first-page":"A3","article-title":"Risk stratification for cardiovascular events in the improve-it trial","volume":"65","author":"Bohula May","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD012502.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2010.03.004","article-title":"An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design","volume":"159","author":"Califf","year":"2010","journal-title":"American Heart Journal"},{"issue":"25","key":"10.1002\/14651858.CD012502.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012502.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes","volume":"156","author":"Cannon","year":"2008","journal-title":"American Heart Journal"},{"issue":"23","key":"10.1002\/14651858.CD012502.pub2-BIB0034|cit34","first-page":"2109","article-title":"IMPROVE-IT Trial: A comparison of ezetimibe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes","volume":"130","author":"Cannon","year":"2014","journal-title":"Circulation"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012502.pub2-BIB0035|cit35","first-page":"A18895","article-title":"Association of type of presentation, STEMI vs NSTEMI\/UA, with the relative long-term incidence of cardiovascular and non-cardiovascular mortality","volume":"134","author":"Fanaroff","year":"2016","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD012502.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"e005840","DOI":"10.1161\/JAHA.117.005840","article-title":"Competing risks of cardiovascular versus noncardiovascular death during long-term follow-up after acute coronary syndromes","volume":"6","author":"Fanaroff","year":"2017","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD012502.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"A4","DOI":"10.1016\/S0735-1097(15)60004-3","article-title":"Baseline LDL-C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS","volume":"65","author":"Giugliano","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD012502.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol : A prespecified analysis of the IMPROVE-IT Trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Crdiology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0040|cit40","first-page":"181","article-title":"Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: A prespecified analysis from the IMPROVE IT trial","volume":"36","author":"Giugliano","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Kato ET Cannon CP Blazing MA Bohula E Guneri S White JA Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Journal of the American Heart Association 2017 e006901","DOI":"10.1161\/JAHA.117.006901"},{"issue":"SUPPL 3","key":"10.1002\/14651858.CD012502.pub2-BIB0042|cit42","first-page":"A17862","article-title":"Benefit and safety of adding ezetimibe to statin therapy on cardiovascular outcomes in 4416 women in the IMPROVE-IT trial","volume":"132","author":"Kato","year":"2015","journal-title":"Circulation"},{"issue":"SUPPL 3","key":"10.1002\/14651858.CD012502.pub2-BIB0043|cit43","first-page":"A13035","article-title":"Impact of ezetimibe on hospitalization-related costs among patients with a recent acute coronary syndrome: Results from the improve-it trial","volume":"132","author":"Magnuson","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD012502.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the IMPROVE-IT Trial","volume":"67","author":"Murphy","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0045|cit45","unstructured":"NCT00202878 IMPROVE-IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe\/simvastatin) vs simvastatin https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00202878"},{"issue":"5","key":"10.1002\/14651858.CD012502.pub2-BIB0046|cit46","first-page":"e003201","article-title":"Impact of ezetimibe on the rate of cardiovascular-related hospitalizations and associated costs among patients with a recent acute coronary syndrome: Results from the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"10","author":"Pokharel","year":"2017","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0047|cit47","unstructured":"Qamar A Giugliano RP Blazing MA Park JG Murphy SA Cannon CP Biomarkers, cardiovascular outcomes and effect of ezetimibe after acute coronary syndrome in the IMPROVE-IT trial Circulation 2017"},{"issue":"13 SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0735-1097(16)30485-5","article-title":"Long term significance of heart failure complicating acute myocardial infarction in 11,185 patients from the improved reduction of outcomes: Vytorin efficacy international trial (IMPROVE-IT)","volume":"67","author":"Silverman","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012502.pub2-BIB0049|cit49","first-page":"1205","article-title":"Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate","volume":"37","author":"Stanifer","year":"2016","journal-title":"European Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD012502.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1681\/ASN.2016090957","article-title":"Benefit of ezetimibe added to simvastatin in reduced kidney function","volume":"28","author":"Stanifer","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0051|cit51","unstructured":"U.S. Food Drug Administration 2015 Meeting materials, Endocrinologic and Metabolic Drugs Advisory Committee. December 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee https:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/ucm426278.htm"},{"issue":"SUPPL 3","key":"10.1002\/14651858.CD012502.pub2-BIB0052|cit52","first-page":"A19694","article-title":"Reduction in non-hemorrhagic stroke with ezetimibe\/simvastatin compared with simvastatin alone in the IMPROVE-IT trial","volume":"132","author":"Wiviott","year":"2015","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Katoh A Hattori Y Yoshikwa N Niiyama H Harada H Kai H The effects of ezetimibe on coronary plaque volume in patients with stable angina pectoris previously treated with statins European Heart Journal 2017 188","DOI":"10.1093\/eurheartj\/ehx501.P857"},{"issue":"3","key":"10.1002\/14651858.CD012502.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5551\/jat.14860","article-title":"Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial","volume":"20","author":"Kinouchi","year":"2013","journal-title":"Journal of Atherosclerosis & Thrombosis"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1097\/01.hjh.0000420710.53898.26","article-title":"Ezetimibe preserves renal function in hypercholesterolemic patients treated with fluvastatin","volume":"30","author":"Kinouchi","year":"2012","journal-title":"Journal of Hypertension"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"O43","DOI":"10.1186\/1532-429X-14-S1-O43","article-title":"Paradoxical changes in lumen size during progression and regression of carotid atherosclerosis","volume":"14","author":"Kodali","year":"2012","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"P178","DOI":"10.1186\/1532-429X-13-S1-P178","article-title":"A reversal of Glagov's hypothesis; A preliminary demonstration by cardiac magnetic resonance","volume":"13","author":"Kodali","year":"2011","journal-title":"Journal of Cardiovascular Magnetic Resonance. Conference"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0058|cit58","first-page":"S61","article-title":"The effect of intensified lipid lowering therapy on one-year prognosis in patients undergoing vascular surgery","volume":"12","author":"Kouvelos","year":"2011","journal-title":"Interactive Cardiovascular and Thoracic Surgery"},{"issue":"1","key":"10.1002\/14651858.CD012502.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248412445506","article-title":"Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study","volume":"18","author":"Kouvelos","year":"2013","journal-title":"Journal of Cardiovascular Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0003319713519492","article-title":"The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery","volume":"66","author":"Kouvelos","year":"2015","journal-title":"Angiology"},{"issue":"25","key":"10.1002\/14651858.CD012502.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"41582","DOI":"10.18632\/oncotarget.15078","article-title":"Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.4238\/2014.April.3.10","article-title":"Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia","volume":"13","author":"Luo","year":"2014","journal-title":"Genetics & Molecular Research"},{"issue":"5","key":"10.1002\/14651858.CD012502.pub2-BIB0063|cit63","first-page":"578","article-title":"Impact of atorvastatin combined with ezetimibe for the treatment of carotid atherosclerosis in patients with coronary heart disease","volume":"32","author":"Luo","year":"2016","journal-title":"Acta Cardiologica Sinica"},{"issue":"11 Suppl 1","key":"10.1002\/14651858.CD012502.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.jacc.2014.07.432","article-title":"Effect of ezetimibe in addition to statin therapy in statin naive STEMI patients assessed by optical coherence tomography and intravascular ultrasound with iMap (the OCTIVUS trial)","volume":"64","author":"Hougaard","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.carrev.2016.11.010","article-title":"Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial","volume":"18","author":"Hougaard","year":"2017","journal-title":"Cardiovascular Revascularization Medicine"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0066|cit66","unstructured":"NCT01385631 Ezetimibe in addition to atorvastatin therapy on the plaque composition in patients with acute myocardial infarction (OCTIVUS) clinicaltrials.gov\/ct2\/show\/NCT01385631"},{"issue":"14 SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"E524","DOI":"10.1016\/S0735-1097(11)60524-X","article-title":"Long-term effect of ezetimibe-statin combination therapy on low-density lipoprotein cholesterol lowering in patients with coronary artery disease; focus on cholesterol absorption and synthesis","volume":"57","author":"Okada","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"21 SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0068|cit68","first-page":"A10846","article-title":"Long-term effects of ezetimibe plus statin combination vs double-dose statin therapy on low-density lipoprotein cholesterol lowering in coronary artery disease patients pre-treated with statins; focus on proprotein convertase subtilisin\/kexin type 9","volume":"126","author":"Okada","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.atherosclerosis.2012.07.036","article-title":"Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease","volume":"224","author":"Okada","year":"2012","journal-title":"Atherosclerosis"},{"issue":"13 SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"E1541","DOI":"10.1016\/S0735-1097(12)61542-3","article-title":"The mechanism of long-term low-density lipoprotein cholesterol lowering effect of ezetimibe-plus-statin combination therapy in coronary artery disease patients; compared with double-dose statin therapy","volume":"59","author":"Okada","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"21 SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0071|cit71","first-page":"A12204","article-title":"Long-term effect of ezetimibe-plus-statin vs double-dose statin on low-density lipoprotein cholesterol lowering in coronary artery disease patients pre-treated with a statin focus on cholesterol absorption and synthesis","volume":"124","author":"Okada","year":"2011","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijcard.2018.04.051","article-title":"Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial","volume":"268","author":"Fujisue","year":"2018","journal-title":"International Journal of Cardiology"},{"issue":"11 SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"A1781","DOI":"10.1016\/S0735-1097(18)32322-2","article-title":"The different effects of statin and ezetimibe combination on coronary atheroma plaque in patients with and without diabetes mellitus: Sub-analysis of precise-IVUS trial","volume":"71","author":"Fujisue","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0074|cit74","unstructured":"NCT01043380 Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01043380"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Nagamatsu S Tsujita K Yamanaga K Sugiyama S Shimomura H Yamashita T Impact of statin-ezetimibe combination on coronary atheroma progression\/regression in patients with and without chronic kidney disease-subanalysis of precise-IVUS trial Circulation 2016 A14740","DOI":"10.1161\/circ.132.suppl_3.13849"},{"issue":"5","key":"10.1002\/14651858.CD012502.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012502.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jjcc.2014.12.011","article-title":"Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"Journal of Cardiology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Tsujita K Yamanaga K Komura N Sakamoto K Sugiyama S Sumida H Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE-IVUS trial Atherosclerosis 2016 367 72","DOI":"10.1016\/j.atherosclerosis.2016.05.025"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0079|cit79","doi-asserted-by":"crossref","unstructured":"Tsujita K Yamanaga K Komura N Sakamoto K Sugiyama S Sumida H Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE-IVUS trial European Journal of Preventive Cardiology 2016 1524 8","DOI":"10.1177\/2047487316655465"},{"issue":"13","key":"10.1002\/14651858.CD012502.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/S0735-1097(16)32133-7","article-title":"Dual lipid-lowering with ezetimibe\/statin as a promising anti-atherosclerotic strategy","volume":"67","author":"Tsujita","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"SUPPL 3","key":"10.1002\/14651858.CD012502.pub2-BIB0081|cit81","first-page":"A13849","article-title":"Impact of statin-ezetimibe combination on coronary atheroma progression\/regression in patients with and without prior statin therapy-subanalysis of precise-IVUS trial","volume":"132","author":"Tsujita","year":"2015","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0082|cit82","doi-asserted-by":"crossref","unstructured":"Yamanaga K Tsujita K Sugiyama S Sumida H Shimomura H Yamashita T The impact of statin-ezetimibe combination therapy in patients with decreased cholesterol absorption ability Circulation 2015","DOI":"10.1161\/circ.132.suppl_3.13048"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0083|cit83","doi-asserted-by":"crossref","unstructured":"Ren Y Zhu H Fan Z Gao Y Tian N Comparison of the effect of rosuvastatin versus rosuvastatin\/ezetimibe on markers of inflammation in patients with acute myocardial infarction Experimental and Therapeutic Medicine 2017 4942 50","DOI":"10.3892\/etm.2017.5175"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1476-511X-12-142","article-title":"RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale","volume":"12","author":"Inazawa","year":"2013","journal-title":"Lipids in Health and Disease"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0085|cit85","first-page":"S82","article-title":"RESEARCH: Superior effect of ezetimibe was sustained on LDL-C level and the rate of achievement of target value in a 52-week analysis","volume":"58","author":"Kawamura","year":"2015","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD012502.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12944-017-0508-4","article-title":"Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects","volume":"16","author":"Sakamoto","year":"2017","journal-title":"Lipids in Health and Disease"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0087|cit87","unstructured":"UMIN000002593 Recognized effect of statin and ezetimibe therapy for achievement LDL-C goal apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000002593"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S1567-5688(11)70858-3","article-title":"Low-dose pravastatin plus ezetimibe verus standard-dose pravastatin: the effect on the carotid atherosclerosis of patients with hypercholesterolemia","volume":"12 (1)","author":"Sawayama","year":"2011","journal-title":"Atherosclerosis Supplements"},{"issue":"6","key":"10.1002\/14651858.CD012502.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1753944713513222","article-title":"Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients","volume":"7","author":"Suzuki","year":"2013","journal-title":"Therapeutic Advances in Cardiovascular Disease"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0090|cit90","unstructured":"UMIN000002935 A community-based surveillance of ezetimibe added to statin therapy for chronic kidney disease patients apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000002935"},{"issue":"7","key":"10.1002\/14651858.CD012502.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1177\/0091270009337011","article-title":"The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study","volume":"49","author":"Meaney","year":"2009","journal-title":"Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD012502.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.hlc.2015.10.012","article-title":"Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease","volume":"25","author":"Wang","year":"2016","journal-title":"Heart, Lung and Circulation"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0093|cit93","doi-asserted-by":"crossref","unstructured":"Wang J Ai XB Wang F Zou YW Li L Yi XL Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease International Angiology 2017 467 73","DOI":"10.23736\/S0392-9590.17.03818-4"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0094|cit94","unstructured":"NCT00587678 Comprehensive magnetic resonance of peripheral arterial disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00587678"},{"issue":"10","key":"10.1002\/14651858.CD012502.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jacc.2011.04.034","article-title":"Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease","volume":"58","author":"West","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0096|cit96","first-page":"192","article-title":"Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR","volume":"12","author":"West","year":"2010","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"issue":"1","key":"10.1002\/14651858.CD012502.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2011.04.005","article-title":"The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline","volume":"218","author":"West","year":"2011","journal-title":"Atherosclerosis"},{"issue":"SUPPL1","key":"10.1002\/14651858.CD012502.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"P382","DOI":"10.1186\/1532-429X-13-S1-P382","article-title":"Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy","volume":"13","author":"West","year":"2011","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1567-5688(10)70910-7","article-title":"An improvement of endothelial dysfunction markers in chronic kidney disease simvastatin\/ezetimibe combined therapy","volume":"11","author":"Carru","year":"2010","journal-title":"Atherosclerosis Supplements"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0100|cit100","unstructured":"NCT00861731 Ezetimibe\/simvastatin combination in proteinuric nephropathy (VICTORY) clinicaltrials.gov\/ct2\/show\/NCT00861731"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0101|cit101","first-page":"104","article-title":"Lipid lowering therapy decreases LDL-S-homocysteinilation levels in chronic kidney desease patients","volume":"279","author":"Pisanu","year":"2012","journal-title":"FEBS Journal"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0102|cit102","first-page":"218","article-title":"Effect of combined simvastatin\/ezetimibe administration on taurine levels and oxidative status in patients CDK","volume":"279","author":"Sanna","year":"2012","journal-title":"FEBS Journal"},{"issue":"4","key":"10.1002\/14651858.CD012502.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00726-012-1223-0","article-title":"Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy","volume":"43","author":"Zinellu","year":"2012","journal-title":"Amino Acids"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.numecd.2014.11.004","article-title":"Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement","volume":"25","author":"Zinellu","year":"2015","journal-title":"Nutrition Metabolism and Cardiovascular Diseases"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jpba.2016.07.025","article-title":"Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease","volume":"129","author":"Zinellu","year":"2016","journal-title":"Journal of Pharmaceutical & Biomedical Analysis"},{"issue":"1","key":"10.1002\/14651858.CD012502.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejps.2012.05.006","article-title":"LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy","volume":"47","author":"Zinellu","year":"2012","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0107|cit107","doi-asserted-by":"crossref","unstructured":"Zinellu A Sotgia S Sotgiu E Assaretti S Baralla A Mangoni AA Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients Nutrition, Metabolism and Cardiovascular Diseases 2017 822 9","DOI":"10.1016\/j.numecd.2017.06.011"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0108|cit108","first-page":"S328","article-title":"Effect of ezetimibe combined with low-dose atorvastain calcium on carotid atherosclerosis in elderly patients with coronary heart disease","volume":"64","author":"Zou","year":"2016","journal-title":"Journal of the American Geriatrics Society"},{"issue":"3","key":"10.1002\/14651858.CD012502.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10557-007-6020-8","article-title":"Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)","volume":"21","author":"Devine","year":"2007","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"23","key":"10.1002\/14651858.CD012502.pub2-BIB0111|cit110","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1093\/eurheartj\/ehs105","article-title":"Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe","volume":"33","author":"Taylor","year":"2012","journal-title":"European Heart Journal"},{"issue":"22","key":"10.1002\/14651858.CD012502.pub2-BIB0110|cit111","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD012502.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1016\/j.jacc.2010.03.017","article-title":"The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration","volume":"55","author":"Villines","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jjcc.2012.03.002","article-title":"Comparison of the efficacy and safety of statin and statin\/ezetimibe therapy after coronary stent implantation in patients with stable angina","volume":"60","author":"Arimura","year":"2012","journal-title":"Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.atherosclerosis.2015.06.007","article-title":"Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography","volume":"241","author":"Auscher","year":"2015","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1002\/14651858.CD012502.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1185\/03007990802365094","article-title":"Long-term (48-week) safety of ezetimibe 10 mg\/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia","volume":"24","author":"Bays","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"9","key":"10.1002\/14651858.CD012502.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/j.transproceed.2008.09.007","article-title":"The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation","volume":"40","author":"Crespo-Leiro","year":"2008","journal-title":"Transplantation Proceedings"},{"issue":"6","key":"10.1002\/14651858.CD012502.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10753-007-9041-3","article-title":"The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation","volume":"30","author":"Dagli","year":"2007","journal-title":"Inflammation"},{"issue":"19","key":"10.1002\/14651858.CD012502.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012502.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1742-1241.2008.01798.x","article-title":"Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years","volume":"62","author":"Dujovne","year":"2008","journal-title":"International Journal of Clinical Practice"},{"issue":"3","key":"10.1002\/14651858.CD012502.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1185\/030079908X273273","article-title":"The efficacy of statin monotherapy uptitration versus switching to ezetimibe\/simvastatin: results of the EASEGO study","volume":"24","author":"Roeters van Lennep","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2013.09.034","article-title":"The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)","volume":"231","author":"Brunner","year":"2013","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1002\/14651858.CD012502.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/10558450-000000000-00000","article-title":"Safety of the combination of intensive cholesterol-lowering therapy with oral anticoagulation medication in elderly patients with atrial fibrillation: a randomized, double-blind, placebo-controlled study","volume":"26","author":"Enajat","year":"2009","journal-title":"Drugs and Aging"},{"issue":"6","key":"10.1002\/14651858.CD012502.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jacl.2016.08.015","article-title":"Model-observational bridging study on the effectiveness of ezetimibe on cardiovascular morbidity and mortality in France: A population-based study","volume":"10","author":"Ferrieres","year":"2016","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/VHRM.S49840","article-title":"Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy","volume":"9","author":"Foody","year":"2013","journal-title":"Vascular Health and Risk Management"},{"issue":"4","key":"10.1002\/14651858.CD012502.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.amjcard.2013.10.038","article-title":"Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe","volume":"113","author":"Habara","year":"2014","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012502.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.amjcard.2012.11.002","article-title":"Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality","volume":"111","author":"Hayek","year":"2013","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0129|cit127","first-page":"no pagination","article-title":"Changes of plaque volume and plaque composition during dual lipid-lowering therapy (atorvastatin+ezetimibe) compared to standard therapy. Study with intravascular ultrasound and virtual histology","volume":"9 EuroPCR Abstr","author":"Kovarnik","year":"2013","journal-title":"EuroIntervention"},{"issue":"6 SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0127|cit128","first-page":"60D","article-title":"Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration - HEAVEN study (ongoing)","volume":"104","author":"Kovarnik","year":"2009","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012502.pub2-BIB0128|cit129","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1253\/circj.CJ-11-0730","article-title":"Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibeadministration: HEAVEN study","volume":"76","author":"Kovarnik","year":"2012","journal-title":"Circulation Journal"},{"issue":"6","key":"10.1002\/14651858.CD012502.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jjcc.2014.02.026","article-title":"Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study","volume":"64","author":"Hiro","year":"2014","journal-title":"Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD012502.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"433","DOI":"10.17219\/acem\/34791","article-title":"The effect of combined ezetimibe\/atorvastatin therapy vs. atorvastatin monotherapy on the erythrocyte membrane structure in patients with coronary artery disease: A pilot study","volume":"25","author":"Jackowska","year":"2016","journal-title":"Advances in Clinical & Experimental Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012502.pub2-BIB0133|cit132","doi-asserted-by":"crossref","first-page":"770","DOI":"10.5603\/KP.a2017.0074","article-title":"The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender","volume":"75","author":"Japaridze","year":"2017","journal-title":"Kardiologia Polska"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0132|cit133","first-page":"15","article-title":"Combination therapy effectiveness of ezetimibe and atorvastatin in patients with acute coronary syndrome","volume":"252","author":"Japaridze","year":"2016","journal-title":"Georgian Medical News"},{"issue":"23","key":"10.1002\/14651858.CD012502.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD012502.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"182","DOI":"10.14712\/fb2011057050182","article-title":"Genetic variants in haem oxygenase-1 and endothelial nitric oxide synthase influence the extent and evolution of coronary artery atherosclerosis","volume":"57","author":"Kral","year":"2011","journal-title":"Folia Biologica (Czech Republic)"},{"issue":"10","key":"10.1002\/14651858.CD012502.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"e001675","DOI":"10.1161\/JAHA.114.001675","article-title":"Effect of switching from statin monotherapy to ezetimibe\/simvastatin combination therapy compared with other intensified lipid-lowering strategies on lipoprotein subclasses in diabetic patients with symptomatic cardiovascular disease","volume":"4","author":"Le","year":"2015","journal-title":"Journal of the American Heart Association"},{"issue":"9","key":"10.1002\/14651858.CD012502.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1016\/j.transproceed.2008.09.046","article-title":"Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia","volume":"40","author":"Lopez","year":"2008","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clinthera.2005.02.011","article-title":"Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study","volume":"27","author":"Masana","year":"2005","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD012502.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/jac\/dkp250","article-title":"A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate - High cardiovascular risk","volume":"64","author":"Masia","year":"2009","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD012502.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1536\/ihj.14-311","article-title":"Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease","volume":"56","author":"Masuda","year":"2015","journal-title":"International Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD012502.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jacc.2005.11.072","article-title":"Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia","volume":"47","author":"McKenney","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"E237","DOI":"10.1016\/j.atherosclerosis.2016.07.017","article-title":"Workshop 3.1: Novel Therapies. Comparative effects of cholesteryl ester transfer protein inhibiton, statin and ezetimibe therapy on atherogenic and protective lipid factors: The ACCENTUATE Trial","volume":"252","author":"Nicholls","year":"2016","journal-title":"Atherosclerosis"},{"issue":"19","key":"10.1002\/14651858.CD012502.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"European Heart Journal"},{"issue":"21","key":"10.1002\/14651858.CD012502.pub2-BIB0144|cit144","first-page":"2","article-title":"Measuring the baseline cholesterol absorption and synthesis marker can predict the LDL-C lowering response to ezetimibe-statin combination therapy in patients with coronary artery disease: A multi-center prospective randomized trial","volume":"122","author":"Okada","year":"2010","journal-title":"Circulation"},{"issue":"13 SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"E687","DOI":"10.1016\/S0735-1097(12)60688-3","article-title":"Assessment of atrial late potentials in patients with hypercholesteremia, to investigate the preventive effect of pitavastatin on atrial fibrillation (Alpina study)","volume":"59","author":"Okuyama","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD012502.pub2-BIB0146|cit146","first-page":"203","article-title":"Utility of treatment with atorvastatin 40 mg plus ezetimibe 10 mg versus atorvastatin 80 mg in reducing the levels of LDL cholesterol in patients with ischaemic stroke or transient ischaemic attack","volume":"62","author":"Palacio","year":"2016","journal-title":"Revista De Neurologia"},{"issue":"6","key":"10.1002\/14651858.CD012502.pub2-BIB0147|cit147","first-page":"E132","article-title":"Effectiveness and tolerability of ezetimibe 10 mg\/d coadministered with statins vs statin dose-doubling in patients at high coronary artery disease risk who are not at target LDL-C on statin monotherapy: The EZE (STAT)(2) trial","volume":"28","author":"Pandey","year":"2008","journal-title":"Arteriosclerosis Thrombosis and Vascular Biology"},{"issue":"4","key":"10.1002\/14651858.CD012502.pub2-BIB0148|cit148","first-page":"275","article-title":"Ezetimibe in combination with a statin does not reduce all-cause mortality","volume":"5","author":"Patel","year":"2013","journal-title":"Journal of Clinical Medicine Research"},{"issue":"11","key":"10.1002\/14651858.CD012502.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/heartjnl-2013-304678","article-title":"High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study","volume":"100","author":"Pauriah","year":"2014","journal-title":"Heart"},{"issue":"21","key":"10.1002\/14651858.CD012502.pub2-BIB0150|cit150","first-page":"2","article-title":"A randomized trial comparing the pleotropic effects of ezetimibe plus moderate dose statin versus high dose statin monotherapy","volume":"122","author":"Pesaro","year":"2010","journal-title":"Circulation"},{"issue":"8 SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0151|cit151","first-page":"152S","article-title":"Cholesterol lowering treatment in atrial fibrillation (AF) reduces MTL atrophy","volume":"65","author":"Pop-Purceleanu","year":"2009","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0152|cit152","doi-asserted-by":"crossref","unstructured":"Pytel E Bukowska B Koter-Michalak M Olszewska-Banaszczyk M Gorzelak-Pabi P Broncel M Effect of intensive lipid-lowering therapies on cholinesterase activity in patients with coronary artery disease Pharmacological Reports 2017 150 5","DOI":"10.1016\/j.pharep.2016.09.016"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijcard.2017.02.099","article-title":"A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin","volume":"235","author":"Ran","year":"2017","journal-title":"International Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD012502.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10557-016-6672-3","article-title":"Rosuvastatin for reduction of myocardial damage during coronary angioplasty - the REMEDY trial","volume":"30","author":"Briguori","year":"2016","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0155|cit155","doi-asserted-by":"crossref","unstructured":"Briguori C Quintavalle C D'Alessio F Donahue M Roscigno G Micco F Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study International Journal of Cardiology 2017 112 8","DOI":"10.1016\/j.ijcard.2017.06.087"},{"issue":"4","key":"10.1002\/14651858.CD012502.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"e0172800","DOI":"10.1371\/journal.pone.0172800","article-title":"The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy","volume":"12","author":"Madonna","year":"2017","journal-title":"PLOS One"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1567-5688(09)70170-9","article-title":"The SANDS trial: the effect of statins with versus without ezetimibe on carotid atherosclerosis in type 2 diabetes","volume":"10","author":"Fleg","year":"2009","journal-title":"Atherosclerosis Supplements"},{"issue":"25","key":"10.1002\/14651858.CD012502.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jacc.2008.10.031","article-title":"Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial","volume":"52","author":"Fleg","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"14","key":"10.1002\/14651858.CD012502.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jama.299.14.1678","article-title":"Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial","volume":"299","author":"Howard","year":"2008","journal-title":"JAMA: Journal of the American Medical Association"},{"issue":"6","key":"10.1002\/14651858.CD012502.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jdiacomp.2011.04.001","article-title":"Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: The SANDS experience","volume":"25","author":"Mete","year":"2011","journal-title":"Journal of Diabetes and its Complications"},{"issue":"5","key":"10.1002\/14651858.CD012502.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacl.2010.07.007","article-title":"Achieving lipid targets in adults with type 2 diabetes: the Stop Atherosclerosis in Native Diabetics Study","volume":"4","author":"Russell","year":"2010","journal-title":"Journal of Clinical Lipidology"},{"issue":"11","key":"10.1002\/14651858.CD012502.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/FPC.0000000000000089","article-title":"The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia","volume":"24","author":"Santos","year":"2014","journal-title":"Pharmacogenetics and Genomics"},{"issue":"7","key":"10.1002\/14651858.CD012502.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.amjcard.2006.10.064","article-title":"Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study","volume":"99","author":"Rossebo","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"13","key":"10.1002\/14651858.CD012502.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2310\/JIM.0b013e3181c9af4b","article-title":"Ezetimibe effect on bone mineral density and markers of bone formation and resorption","volume":"58","author":"Sertbas","year":"2010","journal-title":"Journal of Investigative Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012502.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","article-title":"Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease","volume":"160","author":"Baigent","year":"2010","journal-title":"American Heart Journal"},{"issue":"9784","key":"10.1002\/14651858.CD012502.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"84","key":"10.1002\/14651858.CD012502.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1046\/j.1523-1755.63.s84.4.x","article-title":"Study of Heart and Renal Protection (SHARP)","volume":"63","author":"Baigent","year":"2003","journal-title":"Kidney International, Supplement"},{"issue":"11-12","key":"10.1002\/14651858.CD012502.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.acvd.2008.10.008","article-title":"A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE)","volume":"101","author":"Steg","year":"2008","journal-title":"Archives of Cardiovascular Diseases"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0170|cit170","first-page":"589","article-title":"Does patient counseling enhance the lipid-lowering efficacy of ezetimibe in hypercholesterolemic patients uncontrolled with a statin? The TWICE randomized trial","volume":"28","author":"Steg","year":"2007","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0171|cit171","first-page":"209","article-title":"Treating patients with a prior history of statin related muscle side effects to LDL-C goals using fluvastatin XL alone, or in combination with ezetimibe: A randomized, double blind multicentre study","volume":"28","author":"Stein","year":"2007","journal-title":"European Heart Journal"},{"issue":"18","key":"10.1002\/14651858.CD012502.pub2-BIB0172|cit172","first-page":"905","article-title":"A randomized, double-blind, double-dummy, comparison of efficacy and tolerability of fluvastatin XL alone, ezetimibe alone and the combination, in patients with a history of muscle related side effects with other statins","volume":"114","author":"Stein","year":"2006","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD012502.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjcard.2007.09.099","article-title":"Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins","volume":"101","author":"Stein","year":"2008","journal-title":"American Journal of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD012502.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1185\/03007990802426581","article-title":"Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study","volume":"24","author":"Strony","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"12","key":"10.1002\/14651858.CD012502.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.clinthera.2008.12.008","article-title":"Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients","volume":"30","author":"Strony","year":"2008","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0176|cit176","first-page":"53","article-title":"Efficacy and safety of ezetimibe and low-dose simvastatin as primary treatment for dyslipidemia in peritoneal dialysis patients","volume":"26","author":"Suzuki","year":"2010","journal-title":"Advances in Peritoneal Dialysis"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1161\/ATVBAHA.116.308388","article-title":"Ezetimibe in combination with statins ameliorates endothelial dysfunction in coronary arteries after stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a multicenter randomized controlled trial","volume":"37","author":"Takase","year":"2017","journal-title":"Arteriosclerosis, Thrombosis and Vascular Biology"},{"issue":"1","key":"10.1002\/14651858.CD012502.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/gps.2688","article-title":"One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial","volume":"27","author":"Tendolkar","year":"2012","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1475-2840-12-163","article-title":"Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study","volume":"12","author":"Teramoto","year":"2013","journal-title":"Cardiovascular Diabetology"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.atherosclerosis.2012.09.001","article-title":"Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients","volume":"225","author":"Thongtang","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ahj.2016.06.006","article-title":"Rationale and design of a randomized trial of automated hovering for post-myocardial infarction patients: The HeartStrong program","volume":"179","author":"Troxel","year":"2016","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD012502.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ndt\/gfm620","article-title":"Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study","volume":"23","author":"Turk","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0184|cit183","unstructured":"Landray M Baigent C Leaper C Biochemical safety and efficacy of co-administration of Ezetimibe and Simvastatin among patients with chronic kidney disease: the second UK-heart and renal protection (UK-HARP-II) study Oxford University Research Archive 2003 119 20"},{"issue":"3","key":"10.1002\/14651858.CD012502.pub2-BIB0183|cit184","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/j.ajkd.2005.11.018","article-title":"The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD","volume":"47","author":"Landray","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"17","key":"10.1002\/14651858.CD012502.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jacc.2008.09.002","article-title":"Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia","volume":"52","author":"Graaf","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012502.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2011.05.003","article-title":"Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment","volume":"5","author":"Kuilenburg","year":"2011","journal-title":"Journal of Clinical Lipidology"},{"issue":"7","key":"10.1002\/14651858.CD012502.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/0961203316631631","article-title":"Effect of ezetimibe plus pravastatin on endothelial dysfunction in patients with systemic lupus erythematosus","volume":"25","author":"Vera-Lastra","year":"2016","journal-title":"Lupus"},{"issue":"3","key":"10.1002\/14651858.CD012502.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1185\/030079905X28872","article-title":"Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias","volume":"21","author":"Wierzbicki","year":"2005","journal-title":"Current Medical Research and Opinion"},{"issue":"12 SUPPL 1","key":"10.1002\/14651858.CD012502.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"A1287","DOI":"10.1016\/S0735-1097(14)61287-0","article-title":"Mortality reduction in patients treated with long-term intensive lipid therapy: 20-year follow-up of the familiar atherosclerosis treatment study-observational study","volume":"63","author":"Zhao","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD012502.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jjcc.2014.02.026","article-title":"Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study","volume":"64","author":"Hiro","year":"2014","journal-title":"Journal of Cardiology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0191|cit191","doi-asserted-by":"crossref","unstructured":"Ueda Y Hiro T Hirayama A Komatsu S Matsuoka H Takayama T Effect of ezetimibe on stabilization and regression of intracoronary plaque: the ZIPANGU study Circulation Journal 2017 1611 9","DOI":"10.1253\/circj.CJ-17-0193"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0192|cit192","unstructured":"JPRN-UMIN000002964 Prospective, randomized, open-label, clinical trial comparing fibrate monotherapy and fibrate-ezetimibe combination therapy on progression of atherosclerotic plaques, endothelial function, and markers for anti-inflammatory properties\/obesity\/antioxidative properties apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000002964"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0193|cit193","unstructured":"JPRN-UMIN000011745 Prospective, randomized, open-label, clinical trial comparing rosuvastatin monotherapy and combination therapy with ezetimibe on progression of atherosclerotic plaques and endothelial function apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000011745"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0194|cit194","unstructured":"NCT01086020 Atorvastatin plus Ezetimibe on coronary Plaque Progression (AEPP) clinicaltrials.gov\/ct2\/show\/NCT01086020"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0195|cit195","unstructured":"NCT02588235 Ezetimibe and atorvastatin Therapy on TCFA clinicaltrials.gov\/ct2\/show\/NCT02588235"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0196|cit196","unstructured":"NCT03044665 RAndomized Comparison of efficacy and safety of lipid-lowerING with statin monotherapy versus statin\/ezetimibe combination for high-risk cardiovascular diseases (RACING Trial) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03044665"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0197|cit197","unstructured":"NCT03169985 Usual dose Rosuvastatin plus EZetimibe versus high-dose rosuvastatin on coronary atherosclerotic plaque (Rosuzet-IVUS) clinicaltrials.gov\/ct2\/show\/nct03169985"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0198|cit198","unstructured":"NCT03543774 Lipid-lowering therapies in Vietnamese Chronic Kidney Disease population (VietCKD) clinicaltrials.gov\/ct2\/show\/NCT03543774"},{"issue":"5661","key":"10.1002\/14651858.CD012502.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377(9784)","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012502.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"e0124587","DOI":"10.1371\/journal.pone.0124587","article-title":"Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Battaggia","year":"2015","journal-title":"PLoS One [Electronic Resource]"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0202|cit202","unstructured":"Bloom DE Cafiero ET Jan\u00e9-Llopis E Abrahams-Gessel S Bloom LR Fathima S The Global Economic Burden of Non-communicable Diseases Geneva: World Economic Forum 2011"},{"issue":"25","key":"10.1002\/14651858.CD012502.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"9753","key":"10.1002\/14651858.CD012502.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"9841","key":"10.1002\/14651858.CD012502.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0206|cit206","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD012502.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report","volume":"8","author":"Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members","year":"2014","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0208|cit208","unstructured":"European Medicines Agency (EMA). Committee for Medicinal Products For Human Use Note for guidance on clinical investigation of medicinal products in the treatment of lipid disorders www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003235.pdf (accessed 1 December 2016)"},{"issue":"1","key":"10.1002\/14651858.CD012502.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/jep.12663","article-title":"Addition of ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes","volume":"24","author":"Fei","year":"2018","journal-title":"Journal of Evaluation in Clinical Practice"},{"issue":"10053","key":"10.1002\/14651858.CD012502.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Global Burden of Disease (GBD) 2015 Mortality and Causes of Death Collaborators","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD012502.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7326\/M13-2526","article-title":"Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review","volume":"160","author":"Gudzune","year":"2014","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0214|cit214","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychological Methods"},{"issue":"2","key":"10.1002\/14651858.CD012502.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1- full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-physiol-012110-142233","article-title":"Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport","volume":"73","author":"Jia","year":"2011","journal-title":"Annual Review of Physiology"},{"issue":"14","key":"10.1002\/14651858.CD012502.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012502.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0220|cit220","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012502.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/157016111793744760","article-title":"Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years","volume":"9","author":"Lioudaki","year":"2011","journal-title":"Current Vascular Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012502.pub2-BIB0223|cit223","first-page":"e38","article-title":"Heart disease and stroke statistics - 2016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"issue":"42","key":"10.1002\/14651858.CD012502.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1093\/eurheartj\/ehu299","article-title":"Cardiovascular disease in Europe 2014: epidemiological update","volume":"35","author":"Nichols","year":"2014","journal-title":"European Heart Journal"},{"issue":"26","key":"10.1002\/14651858.CD012502.pub2-BIB0225|cit225","first-page":"445","article-title":"Ezetimibe-statin combination therapy","volume":"113","author":"Nus\u00dfaumer","year":"2016","journal-title":"Deutsches Arzteblatt International"},{"issue":"13","key":"10.1002\/14651858.CD012502.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)","volume":"33","author":"Perk","year":"2012","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0227|cit227","first-page":"415","article-title":"Ezetimibe therapy: mechanism of action and clinical update","volume":"8","author":"Phan","year":"2012","journal-title":"Vascular Health and Risk Management"},{"issue":"9602","key":"10.1002\/14651858.CD012502.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"g4356","DOI":"10.1136\/bmj.g4356","article-title":"Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance","volume":"349","author":"Rabar","year":"2014","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD012502.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutrition, Metabolism and Cardiovascular Diseases"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0231|cit231","unstructured":"Nordic Cochrane Centre; The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"13","key":"10.1002\/14651858.CD012502.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD012502.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and epidemiologic drivers of global cardiovascular mortality","volume":"372","author":"Roth","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"10.1002\/14651858.CD012502.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1161\/CIRCULATIONAHA.114.008720","article-title":"Global and regional patterns in cardiovascular mortality from 1990 to 2013","volume":"132","author":"Roth","year":"2015","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijcard.2015.08.103","article-title":"Safety and efficacy of ezetimibe: A meta-analysis","volume":"201","author":"Savarese","year":"2015","journal-title":"International Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012502.pub2-BIB0236|cit236","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011748.pub2","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","author":"Schmidt","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0237|cit237","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0238|cit238","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention . Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"25 Suppl 2","key":"10.1002\/14651858.CD012502.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"15","key":"10.1002\/14651858.CD012502.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","article-title":"Inhibition of intestinal cholesterol absorption by ezetimibe in humans","volume":"106","author":"Sudhop","year":"2002","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD012502.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1194\/jlr.P900004-JLR200","article-title":"Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and\/or simvastatin in men","volume":"50","author":"Sudhop","year":"2009","journal-title":"Journal of Lipid Research"},{"issue":"12","key":"10.1002\/14651858.CD012502.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/clc.22441","article-title":"Effect of low-density lipoprotein cholesterol lowering by ezetimibe\/simvastatin on outcome incidence: overview, meta-analyses, and meta-regression analyses of randomized trials","volume":"38","author":"Thomopoulos","year":"2015","journal-title":"Clinical Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD012502.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/sj.bjp.0703235","article-title":"Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663","volume":"129","author":"Heek","year":"2000","journal-title":"British Journal of Pharmacology"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0244|cit244","unstructured":"World Health Organization Cardiovascular diseases (CVDs) www.who.int\/mediacentre\/factsheets\/fs317\/en\/"},{"key":"10.1002\/14651858.CD012502.pub2-BIB0245|cit245","unstructured":"World Health Organization Cardiovascular diseases www.who.int\/topics\/cardiovascular_diseases\/en\/"},{"issue":"1","key":"10.1002\/14651858.CD012502.pub2-BIB0246|cit246","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012502","article-title":"Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events","author":"Zhan","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012502.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T06:19:22Z","timestamp":1775283562000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD012502.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Heart Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,11,19]]},"references-count":246,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012502.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,19]]}}}